Literature DB >> 29588357

Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam.

Pranita D Tamma1, Yunfan Fan2, Yehudit Bergman3, Anna C Sick-Samuels4, Alice J Hsu5, Winston Timp2, Patricia J Simner3, Bonnie C Prokesch6, David E Greenberg7,8.   

Abstract

We report our clinical experience treating a 2-month-old infant with congenital diaphragmatic hernia who experienced prolonged bacteremia with Burkholderia cepacia complex (Bcc) despite conventional antibiotic therapy and appropriate source control measures. The infection resolved after initiation of ceftazidime-avibactam. Whole-genome sequencing revealed that the isolate most closely resembled B. contaminans and identified the mechanism of resistance that likely contributed to clinical cure with this agent. Ceftazidime-avibactam should be considered salvage therapy for Bcc infections if other treatment options have been exhausted.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Burkholderia cepacia complex; bacteremia; ceftazidime-avibactam; whole-genome sequencing

Mesh：

Substances：

Year:  2018        PMID： 29588357      PMCID： PMC5913954          DOI： 10.1128/AAC.02213-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.

Authors:  Juyan Zhou; Yunhua Chen; Setareh Tabibi; Luis Alba; Elizabeth Garber; Lisa Saiman
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

2.  Insights into β-lactamases from Burkholderia species, two phylogenetically related yet distinct resistance determinants.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Julian A Gatta; Nozomi Ohuchi; Robert A Bonomo; Michiyoshi Nukaga
Journal:  J Biol Chem       Date:  2013-05-08       Impact factor: 5.157

3.  In vitro activities of antimicrobial agents, alone and in combinations, against Burkholderia cepacia isolated from blood.

Authors:  D C Lu; S C Chang; Y C Chen; K T Luh; W C Hsieh
Journal:  Diagn Microbiol Infect Dis       Date:  1997-08       Impact factor: 2.803

4.  Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen.

Authors:  Krisztina M Papp-Wallace; Scott A Becka; Magdalena A Taracila; Elise T Zeiser; Julian A Gatta; John J LiPuma; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

5.  In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

Authors:  Shazad Mushtaq; Marina Warner; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2010-08-26       Impact factor: 5.790

6.  Naturally occurring Class A ss-lactamases from the Burkholderia cepacia complex.

Authors:  Laurent Poirel; José-Manuel Rodriguez-Martinez; Patrick Plésiat; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 7.  Antibiotic resistance in Burkholderia species.

Authors:  Katherine A Rhodes; Herbert P Schweizer
Journal:  Drug Resist Updat       Date:  2016-07-30       Impact factor: 18.500

8.  Extreme antimicrobial Peptide and polymyxin B resistance in the genus burkholderia.

Authors:  Slade A Loutet; Miguel A Valvano
Journal:  Front Microbiol       Date:  2011-07-22       Impact factor: 5.640

9.  Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species.

Authors:  Annelien Everaert; Tom Coenye
Journal:  Antimicrob Resist Infect Control       Date:  2016-11-16       Impact factor: 4.887

Review 10.  Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

Authors:  Philippe Lagacé-Wiens; Andrew Walkty; James A Karlowsky
Journal:  Core Evid       Date:  2014-01-24
View more
  11 in total

Review 1.  Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.

Authors:  David Aguilera-Alonso; Luis Escosa-García; Jesús Saavedra-Lozano; Emilia Cercenado; Fernando Baquero-Artigao
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates.

Authors:  Elise T Zeiser; Scott A Becka; Brigid M Wilson; Melissa D Barnes; John J LiPuma; Krisztina M Papp-Wallace
Journal:  J Clin Microbiol       Date:  2019-07-26       Impact factor: 5.948

Review 3.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

4.  Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports.

Authors:  Suzan S Asfour; Faisal A Alaklobi; Adli Abdelrahim; Muhammed Y Taha; Raneem S Asfour; Thanaa M Khalil; Mountasser M Al-Mouqdad
Journal:  J Pediatr Pharmacol Ther       Date:  2022-02-09

5.  Ceftazidime-Avibactam as Salvage Therapy in Pediatric Liver Transplantation Patients with Infections Caused by Carbapenem-Resistant Enterobacterales.

Authors:  Weili Wang; Rongrong Wang; Yuntao Zhang; Lei Zeng; Haisen Kong; Xueli Bai; Wei Zhang; Tingbo Liang
Journal:  Infect Drug Resist       Date:  2022-06-25       Impact factor: 4.177

Review 6.  Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach.

Authors:  Lorena van den Bogaart; Oriol Manuel
Journal:  Antibiotics (Basel)       Date:  2022-05-02

7.  Pharmacoepidemiology of Ceftazidime-Avibactam Use: A Retrospective Cohort Analysis of 210 US Hospitals.

Authors:  Jeffrey R Strich; Emily Ricotta; Sarah Warner; Yi Ling Lai; Cumhur Y Demirkale; Samuel F Hohmann; Chanu Rhee; Michael Klompas; Tara Palmore; John H Powers; John P Dekker; Jennifer Adjemian; Roland Matsouaka; Christopher W Woods; Robert L Danner; Sameer S Kadri
Journal:  Clin Infect Dis       Date:  2021-02-16       Impact factor: 9.079

Review 8.  New Perspectives on Antimicrobial Agents: Cefiderocol.

Authors:  Erin K McCreary; Emily L Heil; Pranita D Tamma
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 9.  Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam.

Authors:  Matteo Bassetti; Maddalena Peghin; Alessio Mesini; Elio Castagnola
Journal:  Infect Drug Resist       Date:  2020-06-12       Impact factor: 4.003

10.  Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.